Phathom Pharmaceuticals, Inc. (PHAT) Stock Price, Financials & Summary

Price chart

Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21

Key dataOct 21, 2026

Open$7.31

From 52W high−60.12%

Volume67001.00

Market cap$583.30M

P/E (TTM)—

P/S (TTM)2.4x

Div yield—

Key dataOct 21, 2026

Open

$7.31

From 52W high

−60.12%

Volume

67001.00

Market cap

$583.30M

ValuationView details →

P/E (Fwd)

21.0x

EV/EBITDA

−16.2x

P/E (TTM)

—

RSI (14)

48.3

MomentumView details →

1D Return

−1.37%

YTD Return

−55.58%

SummaryUpdated Jun 1, 2026

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Florham Park, New Jersey. The company went public in October 2019 and focuses on developing and commercializing novel treatments for gastrointestinal diseases. Phathom's primary asset is <b>VOQUEZNA</b> (vonoprazan), a potassium-competitive acid blocker that represents a new class of acid-suppressing medications for treating stomach acid-related conditions. The company has successfully launched VOQUEZNA in the United States and is working to expand its commercial footprint while developing additional indications for the drug.

Ask drillr about Phathom Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

21.0x

P/E (TTM)

—

EV/EBITDA

−16.2x

EV/Sales

2.4x

P/S (TTM)

2.4x

P/B (TTM)

−1.7x

ProfitabilityView details →

Gross Margin

82.92%

Net Margin

−41.34%

EBITDA Margin

−14.66%

ROE (TTM)

28.78%

ROA (TTM)

−30.29%

Asset Turnover

0.76x

GrowthView details →

Revenue YoY

+110.16%

EPS YoY

+72.94%

FCF YoY

+86.63%

Revenue CAGR 3Y

+1502.37%

EPS CAGR 3Y

+42.72%

EBITDA YoY

+86.31%

MomentumView details →

1D Return

−1.37%

YTD Return

−55.58%

1Y Return

−47.36%

RSI (14)

48.3

vs 50D SMA

−9.02%

vs 200D SMA

−31.90%

Capital & dividendView details →

Debt/Equity

−0.49x

Current Ratio

1.92x

Quick Ratio

1.87x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.21

EPS Surprise

−19.60%

Beats (12Q)

5/12

Next Q EPS Est

−$0.03

Avg Surprise (4Q)

−57.22%

Rev Surprise

−0.32%

Financials snapshotView financials →

Revenue (TTM)

239.66M

Net Income (TTM)

−99.07M

Op. CF (TTM)

−36.69M

Next earningsOct 29, 2026 →

Latest newsMore news →

Phathom Pharmaceuticals initiated patient screening in the registrational Phase 3 pHalcon-NERD-302 study evaluating as-needed VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive GERD.22d ago

Similar companies

Shattuck Labs, Inc.STTK CorMedix Inc.CRMD MiMedx Group, Inc.MDXG Puma Biotechnology, Inc.PBYI DBV Technologies S.A.DBVT Faeth Therapeutics, Inc.FTH Find similar companies →

Latest newsMore news →

Phathom Pharmaceuticals announced that it will present three analyses of VOQUEZNA at the American College of Gastroenterology 2026 Annual Scientific Meeting, covering real-world patient characteristics, efficacy across BMI subgroups and cost-effectiveness in erosive esophagitis.13d ago Phathom Pharmaceuticals initiated patient screening in the registrational Phase 3 pHalcon-NERD-302 study evaluating as-needed VOQUEZNA (vonoprazan) tablets in adults with Non-Erosive GERD.22d ago